SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)

Abstract Background A substantial number of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) experience adverse events after TAVI, with health care expenditure. We aimed to investigate cardiac remodeling and long-term outcomes in diabetic patients w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari, Claudio Montalto, Monika Shumkova, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Nurcan Baydaroglu, Andrea Raffaele Munafò, Daniele Oreste D’Atri, Matteo Casenghi, Lucia Scisciola, Michelangela Barbieri, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Martin Penicka, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio Bartorelli, Carmine Pizzi, Tullio Palmerini, Marc Vanderheyden, Francesco Saia, Flavio Ribichini, Emanuele Barbato
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Series:	Cardiovascular Diabetology
Subjects:	Aortic stenosis TAVI SGLT2i Cardiac damage staging Low-flow low-gradient Cardiac remodeling
Online Access:	https://doi.org/10.1186/s12933-024-02504-8
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)

Similar Items